Polio Working Group



Paternina-Caicedo A, Driessen J, Roberts M, van Panhuis WG. Heterogeneity Between States in the Health and Economic Impact of Measles Immunization in the United States. Open Forum Infectious Diseases, 1 July 2018:5(7). doi: 10.1093/ofid/ofy137. URL


Van Panhuis WG, Paul P, Emerson C, Grefenstette J, Wilder R, Herbst AJ, Heymann D, Burke DS.  A systematic review of barriers to data sharing in public health.  BMC Public Health, 14(1): 1144, Nov 5, 2014. [Epub ahead of print.] PubMed PMID: 25377061.



Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SGF, Cochi SL, Kim JH, Thompson KM. Expert review on poliovirus immunity and transmission.  Risk Analysis, 33(4): 544-605, Apr 2013. doi: 10.1111/j.1539-6924.2012.01864.x

Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SGF, Cochi SL, Kim JH, Thompson KM. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Analysis, 33(4): 606-646, Apr 2013. doi: 10.1111/risa.12031

Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SGF, Cochi SL, Thompson KM. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).  Risk Analysis, 33(4): 680-702, Apr 2013. doi: 10.1111/risa.12022

Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SGF, Cochi SL, Thompson KM.  Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Analysis, 33(4): 703-749, Apr 2013. doi: 10.1111/risa.12044

Lowther SA, Roesel S, O'Connor P, Landaverde M, Oblapenko G, Deshevoi S, Ajay G, Buff A, Safwat H, Salla M, Tangemann R, Khetsuriani N, Martin R, Wassilak S. World Health Organization regional assessments of the risks of poliovirus outbreaks. Risk Analysis, 33(4): 664-679, Apr 2013. doi: 10.1111/risa.12032

Thompson KM.  Modeling poliovirus risks and the legacy of polio eradication. Risk Analysis, 33(4): 505-515, Apr 2013.  doi: 10.1111/risa.12030 

Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim JH, Cochi SL.  Preeradication vaccine policy options for poliovirus infection and disease control. Risk Analysis, 33(4): 516-543, Apr 2013. doi: 10.111/risa.12019

Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses.  Risk Analysis, 33(4): 647-663, Apr 2013. doi: 10.1111/j.1539-6924.2012.01891.x



Closser S, Rosenthal A, Parris T, Maes K, Justice J, Cox K, Luck MA, Landis RM, Grove J, Tedoff P, Venczel L, Nsubuga P, Kuzara J, Neergheen V.  Methods for evaluating the impact of vertical programs on health systems: protocol for a study on the impact of the global polio eradication initiative on strengthening routine immunization and primary health care.  BMC Public Health, 12:728, Sep 1, 2012.  doi: 10.1186/1471-2458-12-728

Closser S.  "We Can't Give Up Now": global health optimism and polio eradication in Pakistan.  Med Anthropol, 31(5):385-403, 2012.  doi: 10.1080/01459740.2011.645927

Grassly NC, Jafari H, Bahl S, Sethi R, Deshpande JM, Wolff C, Sutter RW, Aylward RB.  Waning intestinal immunity after vaccination with oral poliovirus vaccines in India.  J Infect Dis, 205(10):1554-61, May 2012.  doi: 10.1093/infdis/jis241

Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathogens, 8(4):e1002599, Apr 2012.  DOI: 10.1371/journal.ppat.1002599

Kalkowska DA, Duintjer Tebbens RJ, Thompson KM.  The probability of undetected wild poliovirus circulation after apparent global interruption of transmission. Am J Epidemiol, 175(9):936-949, Mar 2012.  doi:10.1093/aje/kwr399

O'Reilly KM, Durry E, ul Islam O, Quddus A, Abid N, Mir TP, Tangermann RH, Aylward RB, Grassly NC.  The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001-11: a retrospective analysis.  Lancet, 380:491-98, Aug 2012.

Patel MK, Konde MK, Didi-Ngossaki BH, Ndinga E, Yogolelo R, Salla M, Shaba K, Everts J, Armstrong GL, Daniels D, Burns C, Wassilak S, Pallansch M, Kretsinger K.  An outbreak of wild poliovirus in the Republic of Congo, 2010-2011.  Clin Infect Dis, 55(10):1291-8, Nov 15, 2012.  doi: 10.1093/cid/cis714

Thompson KM. The role of risk analysis in polio eradication: modeling possibilities, probabilities and outcomes to inform choices. Expert Rev Vaccines, 11(1):5-7, 2012.

Thompson KM, Wallace GS, Tebbens RJ, Smith PJ, Barskey AE, Pallansch MA, Gallagher KM, Alexander JP, Armstrong GL, Cochi SL, Wassilak SG. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Rep, 127(1):23-37, Jan-Feb 2012.

Thompson KM, Duintjer Tebbens RJ.  Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation.  Expert Rev Vaccines, 11(4):449-459, Apr 2012.



Doshi SJ, Sandhu HS, Venczel LV, Hymbaugh KJ, Deshpande JM, Pallansch MA, Bahl S, Wenger JD, Cochi SL.  Poliomyelitis-related case-fatality ratio in India, 2002-2006.  Clin Infect Dis, 53(1):13-19, Jul 1, 2011.  doi: 10.1093/cid/cir332

Kidd S, Goodson JL, Aramburu J, Morais A, Gaye A, Wannemuehler K, Buffington J, Gerber S, Wassilak S, Uzicanin A.  Poliomyelitis outbreaks in Angola genetically linked to India: risk factors and implications for prevention of outbreaks due to wild poliovirus importations. Vaccine, 29(21):3760-6, May 12, 2011. doi: 10.1016/j.vaccine.2011.03.034

O'Reilly KM, Chauvin C, Aylward RB, Maher C, Okiror S, Wolff C, Nshmirimana D, Donnelly CA, Grassly NC.  A statistical model of the international spread of wild poliovirus in Africa used to predict and prevent outbreaks.  PLoS Med, 8(10):e1001109, Oct 2011.  doi: 10.1371/journal.pmed.1001109

Rahmandad H, Hu K, Duintjer Tebbens RJ, Thompson KM.  Development of an individual-based model for polioviruses: implications of the selection of network type and outcome metrics. Epidemiol Infect, 139(6):836-848, Jun 2011.  doi: 10.1017/S0950268810001676

Wassilak S, Pate MA, Wannemuehler K, Jenks J, Burns C, Chenoweth P, Abanida EA, Adu F, Baba M, Gasasira A, Iber J, Mkanda P, Williams AJ, Shaw J, Pallansch M, Kew O.  Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population.  J Infect Dis, 203(7):898-909, Apr 1, 2011.  doi: 10.1093/infdis/jiq140



Duintjer Tebbens RJ. Pallansch MA, Cochi SL, Wassilak SGF, Linkins J, Sutter RW, Aylward RB, Thompson KM.  Economic analysis of the global polio eradication initiative. Vaccine, 29(2):334–343. Dec 2010.  doi:10.1016/j.vaccine.2010.10.026

Emerson CI, Singer PA.  Is there an ethical obligation to complete polio eradication?  Lancet, 375(9723):1340-1, Apr 17, 2010.

Grassly NC, Jafari H, Bahl S, Durrani S, Wenger J, Sutter RW, Aylward BR.  Asymptomatic wild-type poliovirus infection in India among children with previous oral poliovirus vaccination.  J Infect Dis, 201(10):1535-43, May 15, 2010.  doi: 10.1086/651952

Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Mwanza M, Corander J, Garnier S, Chauvin C, Abanida E, Pate MA, Adu F, Baba M, Grassly NC.  Implications of a circulating vaccine-derived poliovirus in Nigeria.  N Engl J Med, 362(25):2360-9, Jun 24, 2010.  doi: 10.1056/NEJMoa0910074

Tebbens RJ, Pallansch MA, Alexander JP, Thompson KM.  Optimal vaccine stockpile design for an eradicated disease: application to polioVaccine, 28(26):4312-27.  doi:10.1016/j.vaccine.2010.04.001

Wassilak S, Orenstein W.  Challenges faced by the global polio eradication initiative.  Expert Rev Vaccines, 9(5):447-9, May 2010.  doi: 10.1586/erv.10.45



Grassly NC, Jafari H, Bahl S, Durrani S, Wenger J, Sutter RW, Aylward RB.  Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India.  J Infect Dis, 200(5):794-801, Sep 1, 2009.  doi:  10.1086/605330

Rainey JJ, Bhatnagar P, Estivariz CF, Durrani S, Galway M, Sandhu H, Bahl S, Jafari H, Wenger J.  Providing monovalent oral polio vaccine type 1 to newborns: findings from a pilot birth-dose project in Moradabad district, India.  Bull World Health Organ, 87:955-959, 2009.  doi: 10.2471/BLT.08.061556



Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward BR, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL, Thompson KM.  Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management.  Risk Analysis, 28(4):855-76, Aug 2008.  doi: 10.1111/j.1539-6924.2008.01078

Grassly NC, Fraser C.  Mathematical models of infectious disease transmission.  Nat Rev Microbiol, 6(6):477-87, Jun 2008.  doi: 10.1038/nrmicro1845

Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Abanida EA, Koleosho-Adelekan T, Grassly NC.  Effectiveness of immunization against paralytic poliomyelitis in Nigeria.  N Eng J Med, 359(16):1666-74, Oct 16, 2008.  doi: 10.1056/NEJMoa0803259

Thompson KM, Duintjer Tebbens RJ.  The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation.  Medscape J Med, 10(8):190, 2008. 

Thompson KM, Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Alexander J, Jafari H, Cochi SL. The risks, costs, and benefits of possible future global policies for managing polioviruses.  Am J Public Health, 98(7):1322-30, Jul 2008.  doi: 10.2105/AJPH.2007.122192